17.7 C
New York
Wednesday, June 17, 2026

Tag: description

Millicom (Tigo) Q2 2025 Earnings Release

Millicom (Tigo) Q2 2025 Earnings Release

Suominen Corporation’s Half-Year Financial Report for January 1 – June 30, 2025: Performance impacted by trade environment, cost saving program progressing

Suominen Corporation’s Half-Year Financial Report on August 7, 2025, at 9:30 a.m. (EEST)

Suominen Corporation’s Half-Year Financial Report for January 1 – June 30, 2025:

Cargojet Announces Second Quarter Financial Results

MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Cargojet Inc. ("Cargojet" or the "Corporation") (TSX: CJT) today announced financial results for the second quarter ended...

SPARTAN DELTA CORP. ANNOUNCES SECOND QUARTER 2025 RESULTS AND OPERATIONS UPDATE

CALGARY, AB, Aug. 6, 2025 /CNW/ - Spartan Delta Corp. ("Spartan" or the "Company") (TSX: SDE) is pleased to report its unaudited financial and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Diversified Royalty Corp. Announces Second Quarter 2025 Results and Strongest Adjusted Revenue(1) Quarter in its History

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for three months ended June 30, 2025 (“Q2 2025”) and six months ended June 30, 2025.

NuVista Energy Ltd. Announces Second Quarter Results Highlighting Solid Financial and Operating Progress

CALGARY, Alberta, Aug. 06, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. ("NuVista" or the "Company") (TSX: NVA) is pleased to announce financial and operating results for the three and six months ended June 30, 2025, and to provide an update on our operational performance. We have continued to advance our business with the goal of creating top-tier returns for our shareholders. Our predictable and repeatable development plan continues to produce improved capital efficiencies, allowing us to reduce our capital expenditures guidance both this year and next and deliver average annual per share production growth of at least 15%. In the third quarter, we will be ramping up production toward 100,000 Boe/d and our 5-year outlook of growing production to 125,000 Boe/d remains fully in-tact and will be achieved with less capital than originally expected. With respect to returns to shareholders, we have directed over $100 million toward share repurchases in the first half of the year and continue to believe a balanced approach to absolute growth and share repurchases will drive superior total returns.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Form 8.3 – Frenkel Topping Group Plc

Downing LLP
LEI: 213800G3X76VBG9SB504
06 August 2025
Form 8.3 re. Frenkel Topping Group Plc

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Cosmos Health secures financing of up to $300 million to develop an ETH-backed treasury, with remaining proceeds for growth and general working capital

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDescription